Psychiatry & Neurology Doctors in Lebanon, TN Accepting Medicare

3 Psychiatry & Neurology doctors found. Showing 1 - 3

Dr. Michael D Hill, MD Psychiatry & Neurology - Psychiatry Medicare: Accepting Medicare Assignments Practice Location: 1404 Winter Dr, Lebanon, TN 37087 Phone: 615-444-4300    Fax: 615-449-2734

Dr. Sabitha Sunderrao Hudek, MD Psychiatry & Neurology - Psychiatry Medicare: Accepting Medicare Assignments Practice Location: 324 N Maple St, Lebanon, TN 37087 Phone: 615-554-7401    Fax: 615-807-3303

Oleksandr Osipchuk, MD Psychiatry & Neurology - Psychiatry Medicare: Accepting Medicare Assignments Practice Location: 430 W Main St, Lebanon, TN 37087 Phone: 615-444-3836    Fax: 615-552-0089

News Archive

Shire's INTUNIV (Guanfacine) approved by the FDA for treatment of Attention-Deficit/Hyperactivity Disorder

Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, today announced that it has received approval from the US Food and Drug Administration (FDA) for INTUNIV- (guanfacine) Extended Release Tablets for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in children and adolescents aged 6 to 17 years. INTUNIV, a once-daily formulation of guanfacine, is the first selective alpha-2A adrenergic receptor agonist approved for the treatment of ADHD.

Fibrogen reports FG-3019 Phase 2 study results for treatment of pancreatic cancer

FibroGen, Inc. today announced results from a Phase 2 open-label study of FG-3019, an investigational anti-fibrotic antibody, in combination with gemcitabine and erlotinib for the treatment of patients with locally advanced or metastatic pancreatic ductal adenocarcinoma (PDAC).

MRIs can help predict MCI individuals at greatest risk for developing Alzheimer's disease

Using MRI, researchers may be able to predict which adults with mild cognitive impairment are more likely to progress to Alzheimer's disease, according to the results of a study published online and in the June issue of Radiology.

CARMAT signs agreement with Edwards Lifesciences for total artificial heart

CARMAT, the designer and developer of the world's most advanced artificial heart, today announced that it has signed an agreement with Edwards Lifesciences, the global leader in the science of heart valves and hemodynamic monitoring. According to this agreement, CARMAT will be using the Carpentier-Edwards' biological heart valves in its artificial heart.

Trius Therapeutics reaches agreement with FDA under SPA for Phase 3 study of torezolid phosphate for ABSSSI

Trius Therapeutics, Inc. announced today that it has reached agreement with the United States Food and Drug Administration (FDA), under the Special Protocol Assessment (SPA) process, on the design of its planned Phase 3 study for the oral dosage form of torezolid phosphate for treatment of acute bacterial skin and skin structure infections (ABSSSI).

Read more Medical News

› Verified 5 days ago